B lunt cerebrovascular injury (BCVI) is defined by the presence of damage to the carotid arteries (CAs) or vertebral arteries (VAs) as a result of nonpenetrating trauma. Early studies estimated the incidence of BCVI at roughly 0.1% among trauma patients.
and 30%-40%, respectively, 4, 9, 10, 15, 20, 21, 24 with mortality of up to 40%. 11, 14 The 2 most commonly cited references regarding BCVI guidelines are from the Eastern and Western Trauma Associations. 1, 5 Both groups support the initial use of CT angiography (CTA) for screening and state that the findings obtained using this modality may be equivalent to those using digital subtraction angiography (DSA). While recent evidence sheds light on the low sensitivity (51%-68%) and a high false-negative rate (8%-24%) of CTA, much less attention has been paid to the high false-positive rate, where, in the most recently published data, up to 45% of patients are given a false diagnosis. 12, 21, 22 This is of particular importance when considering the potential for iatrogenic hemorrhagic complications associated with the initiation of antithrombotic therapy in polytrauma patients. If the appropriateness of imaging recommendations depends on the adequacy of the screening modality, then CTA may render the aforementioned guidelines moot. In light of these concerns, and with the encouragement of the Western Trauma Association to formulate a local protocol, we initiated a guideline whereby patients with positive CTA findings underwent DSA as a confirmatory test.
Methods
We retrospectively reviewed all patients 18 years and older who had been admitted to the University of Pittsburgh Medical Center Presbyterian Hospital or University of Texas Health Science Center at San Antonio University Hospital, both Level I trauma centers, between June 2013 and November 2015, with BCVI diagnosed on screening CTA. The institutional review boards of both institutions approved this study. According to the updated Denver Screening Criteria protocol, patients were screened for BCVI based on their concomitant traumatic injuries on presentation as well as signs/symptoms consistent with BCVI. 6 CTA of the head and neck was performed using a 64-channel, multidetector CT scanner, and all CT angiograms were read by board-certified neuroradiologists. In all patients diagnosed with BCVI based on CTA findings, DSA was performed within 24 hours of admission and images were read by a fellowship-trained interventionalist who was either a neurosurgeon or neurologist. Antithrombotic therapy was initiated based on initial CTA findings after clearance and discussion by the trauma and neurosurgery services. Given the current recommendations of the Eastern and Western Trauma Associations, which state that "the optimal treatment modality for the treatment of BCVI is as yet undetermined" and that "long-term antiplatelet therapy is preferable to warfarin for its safety and cost profile," in general, our preference was to use antiplatelet medications, namely, 325 mg of aspirin daily, for the treatment of BCVI. We reserved anticoagulation, in the form of a nonbolus intravenous heparin drip followed by transition to oral warfarin, for patients with flow-limiting (> 75%) dissections or a significant amount of associated thrombus as visualized on CTA. In patients without evidence of BCVI on DSA, antithrombotic medications were stopped. In patients in whom catheter angiography confirmed the presence of vessel dissection, our protocol included 3 months of medical treatment with antithrombotic medication followed by repeat CTA. Major complications from DSA were defined as access site hematoma requiring blood transfusion, symptomatic vessel dissection/injury, new postprocedural neurological deficit/stroke, and acute kidney injury secondary to contrast-induced nephropathy. All patient information was de-identified and analyzed in compliance with Health Insurance Portability and Accountability Act regulations.
Baseline demographic and admission clinical data included age, sex, indication for BCVI screening, and BCVI grade on the initial CTA scan. 2 The BCVI grades are as follows: Grade I, mild intimal injury or irregular intima; Grade II, dissection with raised intimal flap/intramural hematoma with luminal narrowing greater than 25%; Grade III, pseudoaneurysm; Grade IV, vessel occlusion/thrombosis; and Grade V, vessel transection. Documentation of a true BCVI was identified through review of subsequent DSA studies and confirmed by radiology reports noting the presence of vascular injury as well as injury grade. In addition, serum creatinine levels were noted before and after CTA and DSA. Missing data were treated as omitted at random. The paired t-test was used to compare creatinine levels before and after CTA and DSA as well as for comparisons of BCVI grades based on CTA versus DSA results in the same patient. The positive predictive value (PPV) of CTA was defined as 1 minus the proportion of DSA Grade 0 (normal imaging findings with no injury) when the CTA grade was I or higher. The false-positive rates were compared for different CTA grades using the chi-square test. Significance was defined a priori as a p < 0.05. Analyses were performed using R software (version 3, GNU Affero General Public License).
Results
The patient population comprised 140 patients (64% males [89/140], mean age 50 years). The most common indication for BCVI screening was the presence of a cervical spine injury (67%). The study cohort presented with a total of 156 BCVIs to the carotid and/or VAs. Of these patients, 127 sustained an injury to a single vessel, 10 suffered injuries to 2 vessels, and 3 presented with injuries to 3 vessels. Based on CTA evaluation, there were 2 injuries to the CCA, 45 injuries to the ICAs, and 109 injuries to the VAs (Table 1) .
Based on confirmatory DSA, the most frequently observed vessel injuries observed in our cohort were VA injuries (63/82), with 27 dissections (BCVI Grades I and II; 33%), 5 pseudoaneurysms (BCVI Grade III; 6%), 30 occlusions (BCVI Grade IV; 37%), and 1 transection (Grade V). The mean CTA BCVI grade was 1.92, which was significantly higher than the mean DSA BCVI grade of 1.44 (p < 0.001). DSA confirmed the same grade BCVI as CTA in 38.5% (60/156) of vessels studied; however, in 51.3% (80/156), the DSA grade was lower than that found on CTA, and in 10.3% (16/156), the DSA grade was demonstrated to be higher than that for initial CTA (Fig. 1) .
The CTA false-positive rate (positive CTA findings but negative DSA findings) was 47.4% of vessels studied (47.9% of patients screened), resulting in an overall PPV of 53% (82/156; Table 2 ). The difference in false-positive rates between the 2 centers included in our study was minimal: 47% of CTA studies performed at the University of Pittsburgh Presbyterian Hospital were proven to have false-positive findings based on confirmatory DSA; the false-positive rate for CTA studies at the University of Texas San Antonio Health Science Center University Hospital was 50%. The PPV of CTA was higher for patients diagnosed with Grade II and Grade IV injuries (PPV 76% and 97%, respectively) compared with those with Grade I injuries (PPV 30%, p < 0.001; Fig. 1 and Table 2 ). In addition, there was a significant difference between the PPV of BCVI found on screening CTA based on the vessel involved, with CTA demonstrating a PPV of 40.4% for injuries involving the CCA/ICAs and 58% for injuries involving the VAs (Table 3 ). In particular, there were no instances of improper diagnosis of BCVI in cases in which VA occlusions were seen on CTA. Finally, the concomitant traumatic injury representing the indication for BCVI screening was a predictor (p = 0.004) of the PPV of BCVI found on CTA (Table 4) ; vessel injuries on CTA secondary to complex skull fractures demonstrated a PPV of only 28% after confirmatory DSA, whereas CTA showed a PPV of 60% for injuries diagnosed in association with cervical spine injuries.
The mean creatinine level before CTA was 0.86 mg/ dl (range 0.4-1.4 mg/dl), which was significantly higher than the creatinine levels after CTA (0.82 mg/dl [range 
Discussion
CTA remains the primary screening modality for BCVI because of its speed, availability, noninvasive nature, safety, relative efficacy, and low cost. Current guidelines support its use; however, the guidelines depend on the sensitivity and specificity of the screening modality. The high false-negative rates reported by other centers call these guidelines into question. The high false-positive rates presented in this paper further support a change to existing guidelines.
In the current study, we found that CTA provided an incorrect BCVI grade in 61.5% of vessels studied with a false-positive rate of 47% among our patient population when compared with DSA. The PPV of CTA was increased for Grade II and Grade IV injuries, compared with Grade I injuries, demonstrating that CTA is more likely to correctly diagnose more severe vascular injuries. In addition, we identified CCA and ICA injuries and the presence of complex skull fractures as particular risk factors for false-positive CTA results. Regarding the cited complications associated with DSA, we observed none. There were no associated strokes. Serum creatinine levels following both CTA and follow-up DSA were, in fact, lower than on initial patient presentation to the trauma bay. While DSA risks are not zero, complications at high-volume centers are low, particularly in young, otherwise healthy, trauma patients.
The utility of performing confirmatory DSA in patients with positive findings on CTA is especially important in the trauma population, in which many individuals present with multisystem injuries. In the experience of Stein and colleagues at the R. Adams Cowley Shock Trauma Center at the University of Maryland School of Medicine, 16 nearly 25% of patients with BCVI were not treated with antithrombotic medications due to concomitant injuries, the most common of which were traumatic brain injury, spinal cord injury, 16 visceral injury, multiple orthopedic injuries, or early mortality. Furthermore, among the individuals who required antithrombotic medications, initiation of therapy was delayed beyond 48 hours in nearly 50% of patients due to traumatic brain injury or imminent surgery. Studies examining the hemorrhagic complications associated with the administration of antithrombotic medications in polytrauma patients with BCVI have yielded conflicting results. No significant difference in hemorrhagic complications and/or safety of initiation of antithrombotic therapy was documented in 3 separate analyses involving institutional reviews. 6, 7, 22 However, a criticism of 2 of the studies is that either patients were not actually started on a regimen of antithrombotic therapy soon after presentation or that the actual time to initiation of therapy was not documented. Other studies have demonstrated serious bleeding complications associated with antithrombotic therapy for the treatment of BCVI, specifically noting increased hemorrhagic events in patients with suspected BCVI who were treated with anticoagulants. These increased rates of hemorrhage span the gamut from 8%-22% to over 50%. 3, 4, 13, [18] [19] [20] 25 If the false-positive rates of CTA are as high as 47%, it is possible that these patients may have been treated for an injury they did not have and derived a complication from a therapy they did not need. In addition, finding no injury on DSA obviates the need for follow-up imaging and out- patient appointments, which minimizes the waste of important resources. A recent publication evaluated a similar protocol of performing confirmatory DSA in patients with a positive CTA result and yielded a similar false-positive rate of 45%, as was found in our analysis. 22 The authors started all patients on a regimen of therapeutic anticoagulation with intravenous heparin, aiming for a partial thromboplastin time of 40-50 seconds based on the diagnosis of BCVI by CTA until DSA could be performed. After the confirmatory DSA, patients continued to receive anticoagulation therapy or were transitioned to antiplatelet therapy based on the vessel involved and injury grade. As we found in our cohort, Shahan et al. found that the vast majority (87%) of false-positive CTA results were associated with Grade I injuries on CTA; however, in contrast to our findings, they noted that VA injuries were more commonly misdiagnosed (57%). 22 In summary, our study has demonstrated that CTA provides an incorrect BCVI grade in 61.5% of cases and has a high false-positive rate of 47.4% (Table 5) . Taken in context with the recently published series by Shahan et al., our findings from 2 different centers confirm that false-positive CTA findings in the setting of BCVI are not isolated to a single group of neuroradiologists. 22 In addition, patients presenting with complex skull fractures were more likely to have false-positive CTA findings than those with cervical spine injuries.
Limitations of this study include its retrospective nature, which inhibited our collection of information, such as hemorrhagic complications from anticoagulation. Other limitations include the application of DSA only in patients with positive CTA findings, thereby inhibiting the calculation of false negatives. Finally, further study is required to determine the reason for our high rate of false-negative readings. For instance, we noted a number of indeterminate or "hedge" readings that were ultimately considered positive CTA findings. This subset requires further attention from our neuroradiologists.
Conclusions
The current findings support the safety and utility of DSA as a confirmatory test to be used in conjunction with CTA in patients with positive, or abnormal, results. To that end, given a false-positive rate of 47.9% with an estimated average of 132 patients per year with positive findings for BCVI with CTA, approximately 63 patients per year would potentially be treated unnecessarily with antithrombotic therapy at a busy United States Level I trauma center. These data also highlight the need for a prospective trial in a larger patient population with at least 2 blinded CTA interpretations performed by those not performing the DSA. Future goals will be to determine the subset of patients who would not require confirmatory DSA, to determine the interobserver variability in CTA interpretation, to elucidate the cause of false-positive radiographic readings, and to contribute to future BCVI screening guidelines, incorporating judicious use of confirmatory DSA. 
